On July 17, Gilead Sciences rose 3.02% in regular trading, trading at $135.685 per share, with turnover of $4.68 billion, tracking broad-based gains across the biotechnology sector.

The move was driven by sector-wide strength among large-cap biotech names, with Gilead's gain largely in lockstep with industry peers. Within the Biotechnology sector, AbbVie rose 3.0%, Amgen gained 2.89%, and Vertex Pharmaceuticals advanced 1.32%, reflecting a coordinated sector rally rather than a company-specific catalyst.

On the fundamental front, Gilead recently secured FDA approval for Trodelvy as a first-line treatment for advanced triple-negative breast cancer, both as monotherapy and in combination with Merck's Keytruda. The NCCN has listed it as a Category 1 preferred first-line option regardless of PD-L1 status. Additionally, HSBC recently upgraded the stock to Buy with a target price of $155, providing valuation support following a prior pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)